Skip to content

Increase in adviser interest in EIS industry – FT Adviser

John Glencross, CEO, Calculus Capital was featured in an FT Adviser article looking into increased adviser interest in the EIS industry. EIS Industry claims steady increase in adviser interest FT Adviser 16/12/15 Statistics from enterprise investment scheme investment firms Deepbridge Capital and Calculus Capital show a steady increase in the number of advisers using in EIS … Continued

Calculus Capital’s reaction to the Finance Act 2015

John Glencross, CEO and Co-Founder, Calculus Capital sums up his thoughts on the Finance Act 2015 and how it will affect the EIS industry and Calculus Capital.“Our thoughts are that there is more complexity and that is unhelpful, but it does not materially impact the type of investments Calculus Capital makes for its EIS funds or … Continued

Synpromics signs $1.5m up front contract with AGTC

We’re delighted to share that our portfolio company Synpromics has signed a contract with US based AGTC. For the full press release please see below.Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, and Synpromics Limited, a leading synthetic … Continued